Table 2.

Cell viability of SH-SY5Y and SK-N-BE(2) after treatment with 0.4 μM BAY 61-3606, chemotherapeutic drugs or combinations of both.

		SH-SY5Y			SK-N-BE(2)
	Treatment	Cell viability (%) Mean ± SD	p value Drug vs. combination	p value BAY vs. combination	Cell viability (%) Mean ± SD	p value Drug vs. combination	p value BAY vs. combination
48 h	0.4 μM BAY	79.01 ± 6.26			94.04 ± 7.72
	Paclitaxel	87.71 ± 7.83			90.89 ± 7.86
	Paclitaxel + BAY	54.65 ± 3.26	<0.001	<0.001	72.98 ± 9.33	<0.001	<0.001
	Cisplatin	82.33 ± 9.01			98.94 ± 6.48
	Cisplatin + BAY	62.47 ± 5.82	<0.001	<0.001	90.49 ± 7.46	0.052	>0.999
	Doxorubicin	100.5 ± 9.59			102 ± 9.68
	Doxorubicin + BAY	77.97 ± 8.01	<0.001	>0.999	93.69 ± 8.78	0.121	>0.999
	Temozolomide	107 ± 11.17			107.7 ± 3.65
	Temozolomide + BAY	76.81 ± 4.82	<0.001	>0.999	100 ± 4.36	0.132	0.181
72 h	0.4 μM BAY	80.20 ± 7.62			96.97 ± 6.89
	Paclitaxel	84.53 ± 4.60			88.29 ± 5.19
	Paclitaxel + BAY	36.79 ± 3.14	<0.001	<0.001	59.48 ± 8.81	<0.001	<0.001
	Cisplatin	73.38 ± 5.89			73.99 ± 2.95
	Cisplatin + BAY	56.25 ± 5.72	<0.001	<0.001	73.53 ± 5.94	>0.999	<0.001
	Doxorubicin	102.2 ± 8.37			101.3 ± 7.56
	Doxorubicin + BAY	78.57 ± 7.16	<0.001	>0.999	93.99 ± 9.68	0.053	>0.999
	Temozolomide	107.7 ± 6.13			102.7 ± 4.28
	Temozolomide + BAY	74.21 ± 5.99	<0.001	0.217	99.74 ± 6.68	>0.999	>0.999

Cell viability was measured by MTT assay after 48 and 72 h. The control was set as 100% viable cells. Data are presented as mean ± SD from at least three independent experiments. Using two-way ANOVA, a significant effect was observed for both treatment and between cell lines p < 0.001; Bonferroni’s multiple comparison test was used to evaluate differences between treatments, and p values < 0.05 were considered as statistically significant.